Nimodipine Altan

Nimodipine, the active ingredient in Nimodipine Altan, is a calcium channel blocker (dihydropyridine) presented as an intravenous solution for hospital use. It is employed to prevent cerebral vasospasm in patients who have suffered a subarachnoid hemorrhage.

GNH USA supplies Nimodipine Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nimodipine is used in the management of cerebrovascular complications, particularly to reduce vasospasm after subarachnoid hemorrhage.

- Subarachnoid hemorrhage (post‑aneurysmal): Prevention of cerebral vasospasm, helping maintain adequate cerebral blood flow. - Delayed cerebral ischemia after SAH: Reduction of risk by improving microvascular perfusion. - Neurocritical care patients at risk of vasospasm: Maintenance of cerebral perfusion to limit secondary brain injury.

Nimodipine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and reddening of the skin. - Hypotension: low blood pressure, especially when administered rapidly. - Nausea: occasional gastrointestinal upset. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical intervention. - Cardiac arrhythmias: irregular heart rhythms, particularly in patients with pre‑existing cardiac disease. - Allergic reactions: rash, itching, or anaphylaxis in rare cases.

When using Nimodipine, clinicians should consider several safety measures. - Cardiovascular monitoring: observe blood pressure and heart rate during infusion. - Concomitant vasodilators: avoid combining with other potent vasodilators without supervision. - Hepatic impairment: dose adjustment may be required in patients with liver dysfunction. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at ambient temperature: keep below 25°C, in the original packaging, protected from moisture and light.

Nimodipine can interact with other medicines, influencing its safety and efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels and risk of toxicity. - Concurrent use with other potent vasodilators: can cause profound hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Beta‑blockers: may mask tachycardia caused by hypotension. - Diuretics: can enhance blood‑pressure‑lowering effect, requiring closer monitoring.